ATC Group: L01XX35 Anagrelide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01XX35 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01X Other antineoplastic agents
4 L01XX Other antineoplastic agents
5 L01XX35 Anagrelide

Active ingredients in L01XX35

Active Ingredient

Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and suppress expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

Related product monographs

Document Type Information Source  
 AGRYLIN Capsule MPI, US: SPL/PLR FDA, National Drug Code (US)
 XAGRID Capsule MPI, EU: SmPC European Medicines Agency (EU)

Medicines in this ATC group

United States (US)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Netherlands (NL)

New Zealand (NZ)

Singapore (SG)

South Africa (ZA)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.